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Abstract
Recently, a clinical study on patients with stable coronary artery disease (CAD) showed that external counterpulsation
therapy (ECP) at high (300 mmHg) but not at low inflation pressure (80 mmHg) promoted coronary collateral growth, most
likely due to shear stress-induced arteriogenesis. The exact molecular mechanisms behind shear stress-induced
arteriogenesis are still obscure. We therefore characterized plasma levels of circulating microparticles (MPs) from these
CAD patients because of their ambivalent nature as a known cardiovascular risk factor and as a promoter of
neovascularization in the case of platelet-derived MPs. MPs positive for Annexin V and CD31CD41 were increased, albeit
statistically significant (P,0.05, vs. baseline) only in patients receiving high inflation pressure ECP as determined by flow
cytometry. MPs positive for CD62E, CD146, and CD14 were unaffected. In high, but not in low, inflation pressure treatment,
change of CD31CD41 was inversely correlated to the change in collateral flow index (CFI), a measure for collateral growth.
MPs from the high inflation pressure group had a more sustained pro-angiogenic effect than the ones from the low inflation
pressure group, with the exception of one patient showing also an increased CFI after treatment. A total of 1005 proteins
were identified by a label-free proteomics approach from MPs of three patients of each group applying stringent
acceptance criteria. Based on semi-quantitative protein abundance measurements, MPs after ECP therapy contained more
cellular proteins and increased CD31, corroborating the increase in MPs. Furthermore, we show that MP-associated factors
of the innate immune system were decreased, many membrane-associated signaling proteins, and the known
arteriogenesis stimulating protein transforming growth factor beta-1 were increased after ECP therapy. In conclusion,
our data show that ECP therapy increases platelet-derived MPs in patients with CAD and that the change in protein cargo of
MPs is likely in favor of a pro angiogenic/arteriogenic property.
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Introduction
In patients with coronary artery disease (CAD), therapeutic
promotion of coronary collateral growth is an attractive option for
re-vascularizing myocardial tissue aside from percutaneous coro-
nary intervention (PCI) and surgical bypass grafting. Collateral
growth, or arteriogenesis, is triggered by increased tangential fluid
shear stress at the endothelium and results in remodeling of pre-
existing arteriolar anastomoses and improved blood flow [1].
Lower-leg, high-pressure external counterpulsation (ECP) trig-
gered during diastole induces a flow velocity signal and thus,
tangential endothelial shear stress in addition to the flow signal
caused by cardiac stroke volume [2,3].
During the last decades, ECP has been shown to be a safe and
effective non-invasive therapy for patients with refractory angina
pectoris [2,3,4], but the underlying mechanisms have not been
clarified yet. Aside from increased collateral growth [5,6], an
improvement of myocardial perfusion [7], endothelial function,
and/or nitric oxide bioavailability [5,8,9,10] have been demon-
strated after ECP treatment. In a recent study where chronic
stable CAD patients were randomly assigned to low (80 mmHg) or
high (300 mmHg) pressure ECP for a total of 30 hours, a
significant increase of collateral function was demonstrated in
the 300 mmHg group [5]. Similar results on collateral function
have been obtained in an open, non-randomized trial of patients
with chronic CAD undergoing 35 hours of ECP [6].
Microparticles (MPs) are shed from cells in response to diverse
stimuli including injury, complement activation, apoptosis or high
shear stress [11]. They are small, spherical vesicles ranging in size
from 0.1–1.0 mm, and originate from endothelial cells, leukocyte,
erythrocytes, and platelets. The main MP pool in human blood is
platelet derived, abbreviated as PMP [12,13]. MPs display cell
surface proteins indicating their cellular origin, e.g. PMPs were
found to be positive for CD31 (platelet endothelial cell adhesion
molecule, PECA1) and CD41 (integrin alpha-IIb, ITA2B). In
humans, plasma levels of circulating MPs are known to increase
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with the presence of cardiovascular risk factors and progression of
atherosclerosis [14]. In contrast, PMPs have also been shown to
promote angiogenesis in vitro through activation of endothelial cells
indicating a potential beneficial effect [15,16,17]. Furthermore,
PMPs may induce monocyte adhesion to endothelial cells by
stimulating the proliferation, survival and adhesion of hematopoi-
etic cells [18]. This in turn induces the release of growth factors
and cytokines triggering inflammation-like processes [19]. Cur-
rently, there is no data available regarding these potential benefits
of PMPs on arteriogenesis or collateral growth.
Given the above stated beneficial therapeutic effects of ECP in
patients with CAD and the many properties related to MPs, we
hypothesized that increased tangential fluid shear stress has an
effect on circulating MPs in vivo and that these MPs are involved in
ECP induced collateral growth. Retrospectively, we sought to
determine plasma levels and the cell-specific origin of MPs
obtained from CAD patients before and after treatment with
either high or low inflation pressure ECP using flow cytometry.
Furthermore, we studied the biological activity of these MPs with
an in vitro angiogenesis assay and characterized the protein
composition by a proteomics approach. Our results indicate to
our knowledge for the first time, that ECP therapy alters the MP
composition towards a pro-angiogenic/pro-arteriogenic property.
Methods
Study design
This investigation was part of a clinical trial evaluating the effect
of ECP therapy on coronary collateral function (www.clinicaltrials.
gov identifier NCT00414297) [5]. The independent institutional
research ethics committee (Kantonale Ethikkommission Bern,
Study No. KEK-BE 61/06) approved this study, and the patients
gave written informed consent before participation. The study
design has been described previously. Here, a subset of fifteen out
of 20 patients from the former ECP study (age 63610 years, 12
men) [5], for which blood plasma samples were available, were
included. Patients had chronic stable one- (n = 1), two- (n = 8) or
three-vessel (n = 6) CAD eligible for percutaneous coronary
intervention (PCI) of at least one stenotic lesion. All patients
underwent diagnostic coronary angiography because of symptoms
related to CAD and were randomly assigned to lower-leg, high
(300 mmHg, n = 7) or low inflation pressure (80 mmHg, n = 8)
ECP treatment, that consisted of 20 sessions of 90 minutes
duration each, given at five days per week during four weeks
( = 30 hours total).
If suitable and possible, pressure-derived collateral flow index
measurements (CFI) [20,21] were performed before and after ECP
treatment in the coronary artery regarded to be the lesion
responsible for the patient’s symptoms (stenosed) and additionally
in an angiographically and functionally normal coronary artery
(normal vessel). In the 80 mmHg group, there were nine normal
and seven stenosed vessel CFI values available, in the 300 mmHg
group six normal and six stenosed. All patients taking medication
at the start of the study continued with their medication
throughout the study period.
Collection of blood samples
At the end of the invasive procedure, arterial blood was
collected from the right femoral artery using the 6F PCI guiding
sheath in 9-mL EDTA tubes (Sarstedt, Germany) supplemented
with protease inhibitor (Roche Applied Sciences, Switzerland).
Blood samples were centrifuged within 15 minutes (20006 g for
20 min at 20uC) and plasma was collected by aspiration at 1 cm
above the cell layer. Plasma was further centrifuged (160006g for
2 min at 20uC) and aliquots of 250 mL or 500 mL were frozen and
stored at 270uC for further analysis. Additionally, venous plasma
samples were collected from healthy control subjects (n = 17).
Characterization of microparticles by flow cytometry
Microparticles (MP) were isolated and incubated with antibod-
ies as described elsewhere [22]. MP suspension aliquots of 5 mL,
each, were separately diluted with 40 mL of a 1:1 mixture of Tris/
PBS buffer (50 mM Tris/HCl pH 7.2/10 mM PBS pH 7.2) and
incubated at room temperature after the addition of 5 mL of the
following monoclonal antibodies and their isotype negative
controls: mouse anti-CD31 (PECAM-1, FITC, Sigma, Germany;
isotype IgG1, Dako, Denmark), mouse anti-CD41 (platelet
glycoprotein llb, RPE, Dako; isotype IgG1, Dako), mouse anti-
CD62E (E-selectin, PE, Santa Cruz, U.S.A; isotype IgG1, Dako),
mouse anti-CD146 (MCAM, PE, BD Biosciences, U.S.A; isotype
IgG1, Dako), mouse anti-CD14 (monocyte, RPE, Dako; isotype
IgG2a k, Dako). For double staining, mouse anti-CD31 and
mouse anti-CD41 were added together. Numbers of MPs were
determined by Annexin V positive staining. Annexin binding
buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2 and 1.8 mM CaCl2, pH 7.4) was used for incubation with
the Annexin V Cy5 (MBL international, Woborn, MA, U.S.A).
Tris/PBS buffer served as Annexin negative control. After
incubation, 900 mL Tris/PBS buffer was added and samples were
analyzed with a LSR II flow cytometer with FACSDiva software
(BD Biosciences, San Jose, California). In order to determine the
flow rate of the flow cytometer, water flow rate was measured for
10 min. Taking dilution into account, numbers of MPs per mL
plasma were calculated based on events per analyses period of
60 sec during a total analysis time of 70 sec. Data were evaluated
by FlowJo software 7.5 (Tree Star, Inc. Oregon, U.S.A.). Assays
were carried out with 5 replicates. Intra-assay and inter-assay
reproducibility was evaluated in 10 independent experiments,
showing an overall coefficient of variation of 13.0% and 10.3%,
respectively (not shown).
Angiogenesis Assay
Matrigel substrate (Millipore, Zug, Switzerland) was distributed
in pre-cooled 96-well tissue culture plates according to the
manufacturer’s recommendations. MPs were isolated and sus-
pended in 500 mL of EBM-2 medium (Lonza, Basel, Switzerland)
and mixed with 3.56104 human umbilical vein endothelial cells
(HUVEC). Aliquots of 150 mL of cell/MP suspension were
distributed in three wells. EBM-2 and growth factor supplemented
EGM-2 media served as controls. Development of tube formation
was recorded with pictures taken of the same well area after 2, 4, 6,
8, 12, and 24 h using a Nikon microscope equipped with a charge-
couple device camera. Each MP sample was measured in
triplicate. The number of meshes and branching points were
counted using ImageJ software. HUVECs were isolated from
umbilical cords here at the local women’s hospital (gift of D.
Surbeck).
MP analysis by mass spectrometry
MPs isolated as described above from 250 mL plasma were lysed
in SDS-PAGE sample buffer and proteins separated on 10% SDS-
PAGE gels. Gels were stained with Sypro RubyH protein gel stain
(Sigma, Buchs, Switzerland), images recorded followed by
destaining of gels. Each sample lane was cut horizontally with a
scalpel accurately into 14 slices per lane, and each slice was cut
into small (,1 mm3) cubes. Each slice was in-gel digested as
described elsewhere [23]. Peptide sequencing was made on a LTQ
Orbitrap XL mass spectrometer (ThermoFisher Scientific, Bre-
External Counterpulsation Alters Microparticles
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men; Germany) equipped with a Rheos Allegro nano flow system
with AFM flow splitting (Flux Instruments, Reinach; Switzerland)
and a nano electrospray ion source operated at a voltage of
1.7 kV. Peptide separation was performed on a Magic C18
column (5 mm, 100 A˚, 0.075670 mm) using a flow rate of
,400 nL/min and a linear gradient of 5 to 40% acetonitrile in
water/0.1% (v/v) formic acid during 60 min. Data acquisition was
in data dependent mode on the top five ions with m/z between
360–1400. Precursor ions were excluded for 15 sec (610 ppm).
Survey full scan MS spectra were recorded in the orbitrap at
resolution 60000 with automatic gain control (AGC) target of
56105 and ion time of 500 ms parallel to precursor ion
fragmentation in the LTQ with the following settings: normalized
collision energy of 30%, isolation width of 4.0 units, ion time of
200 ms, AGC target of 104.
Protein identification and quantification
Mascot generic files were generated by using Hardklo¨r [24].
Database searches were done with Phenyx [25] against the
forward and reversed UniprotKB SwissProt protein database
(Release 2010_12) of human entries applying a two round search
strategy. First round parameters were with a parent error tolerance
of 20 ppm, normal cleavage mode with 1 missed cleavage and
static carbamidomethylation on Cys and one variable oxidation on
Met, respectively. During second round trypsin specificity was
relaxed to half cleaved with 4 missed cleavages and variable amino
acid modifications of carbamidomethylation on Cys, deamidation
of Gln/Asn (maximum of 2 per peptide), oxidation of Met (2), and
pyrrolidone carboxylic acid on n-terminal Asn (1), respectively.
Based on reversed database peptide matches a z-score threshold of
1% peptide false discovery rate together with at least two unique
peptide matches per protein were set as a protein acceptance
criteria. Protein and peptide matches of each MP proteome were
separately exported into MIAPE accepted excel format. Protein
identifications from all samples were compared and annotated to a
single consensus AC based on numbers of unique peptide matches.
This filtering caused the loss of certain protein isoform identifi-
cations and some proteins remained with only one unique peptide
match (Table S1). The peptide match score summation (PMSS)
value for each identified protein was used as a semi-quantitative
abundance estimate [23]. PMSS values were normalized by
division with the median PMSS across all proteins in each sample
and multiplication with the median across all samples. Repeat-
ability of the applied proteomics approach was tested with three
technical MP replicates of the same blood donor resulting in 175
proteins identified in all three runs. Normalized PMSS values
correlated well between runs with linear correlations (R2) of 0.984,
0969, and 0.984 and linear regression slopes of 0.964, 0.984 and
1.02 respectively. The overall coefficient of variation was 26% (not
shown). In this manuscript, we use the SwissProt ID as the protein
name.
Statistical Analyses
Data are given as mean 61 standard deviation (SD). Baseline
characteristics between the groups were analyzed by Mann-
Whitney test for continuous data and by Fisher’s exact test for
categorical data. Two-tailed Wilcoxon signed rank tests were used
for analytical results. A P-value,0.05 was considered as statisti-
cally significant. Matlab (R2010a) software was used.
Results
Patient characteristics and clinical data at baseline
Patient characteristics and clinical data at baseline are presented
in Table 1. Patients presented without statistically significant
differences between the high and low inflation pressure group
regarding age, gender, duration of angina pectoris, history of
myocardial infarction in a remote vascular area, and body mass
index. No difference in the frequency of cardiovascular risk factors
was observed except from family history for CAD (P = 0.04).
Moreover, blood chemistry values including serum lipids did not
differ at baseline between the groups (Table 1) nor between before
(base-line, BL) and after (follow-up, Fup) ECP therapy (Table 2).
The use of acetylsalicylic acid, clopidogrel, vasoactive drugs,
statins or antihypertensive drugs did not differ significantly.
High pressure ECP therapy improves collateral function
in patients suffering from CAD
Collateral flow index increased significantly (P,0.05) from
0.14160.060 to 0.20160.067 after high pressure ECP as
determined in twelve vessels, but not after low pressure ECP
(from 0.12760.091 to 0.13760.063; sixteen vessels).
Effect of ECP therapy on numbers and origin of MPs
Annexin V positive MP counts were more than 3.4-fold higher
(P,0.05) in this study population of CAD patients
(5.1610663.76106 counts/mL; n = 15) than in healthy controls
(1.5610661.06106 counts/mL; n = 17), not shown. High pressure
ECP therapy in CAD patients increased numbers of Annexin V
positive MPs significantly by 1.8-fold (P,0.05; n = 7), while low
pressure ECP therapy resulted in no statistically significant effect
(P = 0.148; n = 8) albeit with a 1.6-fold increase (Figure 1A).
MPs were stained for platelet endothelial cell adhesion molecule
(CD31) and platelet membrane glycoprotein IIb (CD41). CD31
and CD41 positive MPs were both increased 1.6-fold in CAD
patients treated by low pressure ECP (P,0.05), whereas only
CD31 positive MPs increased significantly after high pressure ECP
(1.95-fold; P,0.05), and the CD41+ increase did not reach
statistical significance (1.5-fold; P = 0.078) (Figure 1B and C).
Platelet-derived MPs (PMPs), double stained for CD31 and
CD41, increased significantly in CAD patients who underwent
high pressure ECP (1.6-fold; P,0.05) and tended to increase after
low inflation pressure therapy (1.8-fold; P = 0.055; Figure 1D).
There was no statistically significant correlation between CD31
and CD41 PMPs and intact platelet numbers (Table 2). In
addition, clopidogrel medication, an inhibitor of platelet activa-
tion, did not have any measurable effect on PMP or platelet
numbers (not shown).
There were no statistically significant differences in lipid status
or cell numbers of leukocytes, monocytes and platelets between
baseline and follow-up, respectively. Furthermore, MPs derived
from monocytes (stained for monocyte differentiation antigen
CD14) and endothelial cells (stained with the cell surface
glycoprotein MUC18, CD146, and the endothelial leukocyte
adhesion molecule 1, CD62E or E-selectin) were not affected by
ECP therapy in patients with CAD (Table 2).
Correlation of changes between PMP and CFI
High, but not low, pressure ECP therapy of patients resulted in
an inverse correlation of MP count changes (Fup minus BL values)
positive for CD31, CD41, and CD31CD41, respectively, with the
corresponding CFI changes (all P,0.05, Figure 2, Figure S1). The
Pearson correlation coefficients did not differ significantly enough
when considering all, or only stenosed or non-stenosed vessels
External Counterpulsation Alters Microparticles
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alone (for instance for CD31CD41 double positive MPs with
rstenosed =20.8173, rnon-stenosed =20.695, and rall =20.6742).
However, the CFI increased only in half of the non-stenosed
vessels of the 300 mmHg inflation pressure group. This might
indicate that a pro-arteriogenic effect of ECP therapy might be
more efficient in occluded vessels. Unfortunately, there are not
enough data points available for an unambiguous interpretation of
this tendency.
One patient (#14) had a substantial increase in CFI after low
inflation pressure treatment (marked with a red circle in Figure 2
and Figure S1). There were no significant correlations between
changes of CD62E, CD146, CD14, or Annexin V counts and the
corresponding CFI (data not shown).
MPs of high inflation pressure group have increased pro-
angiogenic properties
Angiogenesis assays with HUVECs using EBM2 and EGM2
medium resulted in fast tube formation within the first four hours
of incubation quantified by mesh and branching point numbers.
Mesh numbers decreased to 48.4617.5% after 12 hours relative
to the value at four hours (Figure S2 and S3). Tube formation was
increased and sustained longer when MPs isolated from individual
patient plasma samples at BL were added to EBM2 (at 8 hours,
BL: 1.0260.28, n = 34; medium alone: 0.7260.22, n = 11;
Students t-test: P = 0.0027). This effect was even more potent
with MPs isolated from the high inflation pressure treatment group
while it was reversed with the low inflation pressure therapy
samples (see P values given in Figure 3). However, MPs of patient
#14 treated with 80 mmHg ECP had a similar property as MPs of
the 300 mmHg group (black dots in Figure 3).
Qualitative MP protein composition assessment
MPs from three patients of each ECP treatment group were
analyzed at baseline and follow-up by a proteomics approach. We
identified a total of 1005 unique proteins, of which 123 were
identified in all twelve samples and 470 proteins in at least half of
them. This latter protein set was assigned ‘core proteins’. We
compared our list of proteins with the ones published recently,
namely circulating plasma MPs from 12 normal human subjects
published by Østergaard et al [26], and from 42 CAD patients by
Table 1. Patient characteristics at start of therapy (baseline, BL) with n = 8 for ECP 80 mmHg and n= 7 for 300 mmHg group,
respectively.
Variable ECP 80 mmHg ECP 300 mmHg P
Age (years) 6765 59613 0.25
Male gender 6 (75%) 6 (86%) 1
Duration of angina (months) 9.5617.2 8.369.6 0.39
History of prior myocardial infarction (%) 2 (25%) 2 (29%) 1
Body mass index (kg/m2) 28.166.3 28.163.9 0.56
Cardiovascular risk factors
Systemic hypertension 5 (63%) 4 (57%) 1
Smoking 1 (13%) 1 (14%) 1
Cumulative pack years 15.0 15.7 0.77
Hypercholesterolemia 7 (88%) 6 (86%) 1
Family history for coronary artery disease 1 (13%) 5 (71%) 0.04
Obesity (BMI.30 kg/m2) 1 (13%) 3 (43%) 0.28
Diabetes mellitus 1 (13%) 2 (29%) 0.57
Blood chemistry values
Total cholesterol (mmol/L) 4.661.3 4.261.0 0.49
Low density lipoprotein cholesterol (mmol/L) 2.961.0 2.560.8 0.18
High density lipoprotein cholesterol (mmol/L) 1.260.2 1.160.3 0.49
Triglycerides (mmol/L) 1.961.2 2.261.7 0.82
Creatinine (mmol/L) 81615 71615 0.15
Fasting glucose (mmol/L) 5.860.5 7.063.3 0.82
Medication
Acetylsalicylic acid 8 (100%) 6 (86%) 0.47
Clopidogrel 4 (50%) 4 (57%) 0.62
Betablockers 4 (50%) 5 (71%) 0.61
Calcium channel blockers 0 (0%) 0 (0%) -
Nitrates 1 (13%) 2 (29%) 0.57
Statins 8 (100%) 7 (100%) 1
ACE inhibitors 4 (50%) 3 (43%) 1
Angiotensin receptor blockers 3 (38%) 2 (29%) 1
Diuretics 2 (25%) 3 (43%) 0.61
doi:10.1371/journal.pone.0046822.t001
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Little et al [27], as well as PMPs from activated platelets by Garcia
et al [28] and endothelial MPs derived from HUVEC by Peterson
et al [29]. Our MP core protein set covered 83.6% of the Little
core and 82.2% of the Østergaard core MP protein sets,
respectively. The coverage was similar when considering all
identified proteins, with 78.8% and 87.7% respectively (Figure S4).
Our MP protein set covered similarly well the Garcia activated
PMP protein set (76.8%) while the endothelial MP protein set of
Peterson was covered only by 35.9% (Figure S4). In summary, 702
proteins ( = 69.9%) from our own complete MP set were
confirmed by at least one of the other proteome studies (Table S1).
We performed gene ontology (GO) enrichment analyses with
the core protein set using Cytoscape 2.8.2-beta2 and the BINGO
2.44 plugin by applying a hyper geometric test coupled with
Benjamini & Hochberg false discovery rate correction. The highest
significant enrichments for cellular localization (Table S2) were found
in the GO terms of cytoplasmic part (including membrane-
bounded vesicles and cytoskeleton), extracellular region, and
platelet alpha granule; for molecular function (Table S3) in protein/
actin binding, GTPase activity and GTP binding, and (endo-)
peptidase inhibitor/regulator activity; for biological processes (Table
S4) in response to wounding (hemostasis/coagulation), acute
inflammatory response/complement activation/innate immune
response, respectively.
Quantitative MP protein composition assessment, core
protein set
Proteins involved in the biological process of inflammatory
response/complement activation/innate immune response, such
as immunoglobulins and complement factors, were statistically
significant down regulated after high, and even more pronounced
Table 2. Plasma levels of blood cell counts, markers, and lipid
levels.
ECP 80 mmHg (n=8) ECP 300 mmHg (n=7)
Cellsa BL Fup Pe BL Fup Pe
leukocytes 6.3361.32 5.9660.19 0.438 5.9062.03 5.4460.19 0.219
monocytes 0.4760.19 0.3960.18 0.063 0.4460.19 0.3560.20 0.313
Platelets 206654 193657 0.945 202645 208639 0.219
Markers
CD146b 2.262.7 0.860.6 0.313 1.061.2 1.060.8 0.813
CD62Eb 2006140 3306150 0.078 120630 1806130 0.297
CD14b 7.064.1 5.564.5 0.461 9.266.3 9.566.0 0.938
hsCRPc 4.2166.19 4.3168.72 0.383 1.4361.85 1.3761.20 0.297
Lipidsd
LDL 2.961.0 2.560.9 0.498 2.560.8 2.260.6 0.590
HDL 1.260.2 1.160.3 0.416 1.160.3 1.160.2 1.00
TG 1.961.2 1.761.3 0.141 2.261.7 1.861.0 0.563
aCell mass is given as g/L, mean6SD.
bCell markers are given as6104 counts/mL, mean6SD.
chsCRP is given as mg/L, mean6SD.
dLDL and HDL associated cholesterol and total triglycerides (TG) are given as
mmol/L, mean 6 SD.
eP is the statistical probability that the measurement of BL are similar to Fup.
doi:10.1371/journal.pone.0046822.t002
Figure 1. Characterization of circulating microparticles (MPs) by flow cytometry. MPs were isolated from plasma of CAD patients before
(BL) and after (Fup) ECP therapy using low (80 mmHg) or high inflation pressure (300 mmHg). A, number of MPs determined by Annexin V. B and C,
CD31 and CD41 positive MPs. D, PMPs double-stained for CD31 and CD41. Whiskers indicate minimum and maximum values. *P,0.05.
doi:10.1371/journal.pone.0046822.g001
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after low pressure ECP therapy (Figure 4). Certain classes of
cellular proteins were up regulated after ECP therapy, e.g.
myosins, tubulins, integrins and platelet markers, corroborating
the increase in MP numbers as measured by flow cytometry
(Figure S5). CD31 (PECA1) appeared to be increased after ECP
therapy, also corroborating flow cytometry results, while CD41
(ITA2B) expression was unchanged (Figure 5). We also found that
Ras-related proteins RAB and Guanine nucleotide binding factors,
both classes of proteins involved in many intracellular signaling
mechanisms, were up-regulate after ECP therapy (Figure 4). Two
other proteins with many known effects on cellular homeostasis,
angiogenesis and arteriogenesis, thrombospondin-1 (TSP1) and
transforming growth factor beta-1 (TGFB1), were potentially
increased in concentration after ECP therapy (Figure 5). Despite
the fact that plasma lipid concentrations were not affected by ECP
therapy (Table 2), we detected a statistically relevant increase
(P,0.05) of Apo(a) and APOB while the group of small
apolipoproteins remained unchanged, or decreased slightly after
80 mmHg treatment (Figure 6).
Discussion
In our present study, we provide evidence that patients with
stable CAD undergoing ECP therapy exhibit, on average,
increased plasma levels of platelet-derived microparticles (PMPs)
stained positive for CD31 and CD41 antigens. Importantly, the
increase in MP numbers was not due to an increase of cells
carrying CD31 antigen (platelets, leukocytes, and monocytes) or
CD41 (platelets), and the increase of MPs was confirmed by semi-
quantitative proteomics data revealing an increase in CD31
(PECA1) and cellular proteins. Furthermore, ECP did not induce
monocyte (CD14) or endothelial cell (CD146 and CD62E) derived
MPs. This was confirmed by a comparison of our MP proteome
with the ones from MPs, PMPs and EMPs as recently published
[26,27,28,29]. We also demonstrate that patients with stable CAD
have higher Annexin V positive MP counts than healthy controls,
which is in agreement with previous studies [14]. Most interest-
ingly, comparing changes between baseline and follow-up of
individual patients, we found that changes in CFI inversely
correlated with PMP count changes only in the high inflation
pressure therapy group. However, one patient (#14) in the low
inflation pressure group had a CFI increase concomitant with only
a small increase in PMP numbers, a trait matching well with the
high inflation pressure group characteristics. Furthermore, isolated
MPs after ECP therapy from this patient had the same stimulating
effect on endothelial cell tube formation in an in-vitro angiogenesis
assay like the follow-up MPs isolated from the high inflation
pressure group (Figure 3). This observation indicates that shear
forces created with low inflation pressure therapy can already be
sufficient for improved collateral vessel blood flow. The similarity
of protein abundance patterns between high and low inflation
pressure MP specimen, as discussed below, supports furthermore
this finding.
The extent of collateral growth appears to be larger in response
to ECP therapy than with other forms of physical [30] or
pharmacological [31] coronary arteriogenesis. Regarding the
cellular mechanisms of collateral growth, it is essential to
distinguish arteriogenesis, defined as remodeling of collateral
arterioles, independent of ischemia and mainly triggered by fluid
shear stress, from angiogenesis, which is capillary sprouting
initiated by tissue ischemia. Our findings point to a possible
involvement of PMPs and their protein cargo in collateral growth,
something not discussed so far in the existing literature.
Additionally, the same PMPs also show a pro-angiogenic property
in an in vitro angiogenesis assay. The effects of circulating MPs on
angiogenesis described so far in the literature are abundant but
inconsistent. It is well known that these effects depend on the
origin of MPs. Lymphocyte- as well as endothelial-derived MPs
were described as either pro- or anti-angiogenic [32,33,34,35].
PMPs, which we found to be increased after ECP therapy, were
previously reported to affect different stages of the angiogenic
response, with a tendency towards a pro-angiogenic net effect even
in the presence of angiogenesis inhibitors [36]. Furthermore,
PMPs stimulated proliferation of cultured human endothelial cells
in a dose-dependent manner and the phospholipids released from
platelets induced endothelial cell migration and tube formation
[15]. Additionally, stimulation of endothelial cells by PMPs in vitro
resulted in cytokine release and expression of adhesion molecules
[37].
One explanation for these observations might be that PMPs act
as active transporters for different factors in the form of proteins,
lipids and messenger RNA [15,38,39,40]. Indeed, we identified
with our proteomics approach after ECP therapy increased
concentrations of platelet markers, integrins (Figure S5), intracel-
Figure 2. Correlation of PMP and CFI changes. Plotted values are
the differences between follow-up and baseline measurements with
platelet-derived microparticle positive for CD31CD41 on the horizontal
axis and collateral flow index (CFI) on the vertical axis. Values are given
for ECP therapy at high (300 mmHg) on top or low inflation pressure
(80 mmHg) at bottom, respectively. Filled triangles represent CFI values
from stenosed and open circles from normal vessels. The same
correlations were detected with MPs stained positive with CD31 or
CD41 alone (Figure S1). The values encircled in red in the 80 mmHg
inflation pressure group belong to patient #14.
doi:10.1371/journal.pone.0046822.g002
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Figure 3. In vitro angiogenesis assay with isolated MPs. Circulating MPs were isolated from patient’s plasma before (BL) and after (Fup) ECP
therapy at 80 mmHg (top row) or 300 mmHg inflation pressure (bottom row). Displayed are numbers of meshes formed by HUVECs relative to the
four-hour time point. The horizontal bars represent the mean value at each time point. The dots in the BL80 and Fup80 plots are the triplicate values
measured for patient#14. The mean values between the 80 mmHg and 300 mmHg inflation pressure were tested for their likelihood to be the same
by Student’s t-test (two-tailed, equal variance) and P values at each time point are given in the bottom row graphs.
doi:10.1371/journal.pone.0046822.g003
Figure 4. MP Protein quantification by label-free proteomics. Expression levels (LOG2 values of normalized protein abundance values) of
cellular signaling proteins (left side) and proteins involved in the innate immune response (right side) are shown in boxplot format. RAS-related
proteins RAB encompass RAB1B, RAB5C, RAB6B, RAB7A, RAB8A, RAB10, RAB11B, RAB15, RB27B, RAB35, RAP1B, and RAP2B, identified in all twelve
analyzed MP samples. Guanine nucleotide binding factors encompass GNA13, GNAI2, GNAQ, GNAZ, GBB1, and GBB2, identified in at least eight MP
samples. Complement factors considered were identified in at least eight MP samples: C1QA, C1QB, C1QC, C1R, C1S, CO2, CO3, CO4A, CO4B, CO5,
CO6, CO7, CO8B, CO8G, CO9, and CFAB. All immunoglobulin heavy and light chains identified in at least 10 MP samples were considered. When one
of the proteins was not identified its value was set at zero for statistical analysis of P values. P values are given below each box if the likelihood for a
statistical difference between BL and Fup was at least 95%.
doi:10.1371/journal.pone.0046822.g004
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lular signaling proteins (Figure 4), and growth factor modulating
proteins TSP1 and TGFB1 (Figure 5). TGFB1 activates mono-
cytes for binding to endothelial cells and it was found up-regulated
at sites of growing collateral vessels in a rabbit hind-limb
arteriogenesis model [41]. TSP1 is an extracellular matrix protein
that binds many growth factors and acts as a pleiotropic growth
regulator affecting morphogenesis and homeostasis of vessel cells
[42]. We also detected an increase in Apo(a) and APOB, that
together form at a 1:1 ratio lipoprotein(a) particles. Our MP
isolation protocol can potentially sediment lipoproteins together
with MPs. Lipoprotein(a) particles have in average a lower density
than high-density lipoprotein (HDL) particles that are composed of
many small apolipoproteins and have a higher protein to lipid
ratio. It has been reported that CD36 can interact with major
lipoprotein classes, most likely through their lipid cargo as well as
oxidized lipids carried by low-density lipoproteins [43]. CD36 was
identified as a protein component of MPs with our proteomics
approach (Figure S5). Although we do not have any direct
evidence, our finding of an increase in Apo(a)/APOB concomi-
tantly with unchanged small apolipoprotein concentrations in the
MP fraction indicates that lipoprotein(a) might interact more
strongly than HDL with PMPs possibly through CD36. Further-
more, we have recently shown that medium sized Apo(a) is a
marker for good myocardial collaterization [44]. Whether Apo(a),
or special lipids carried by it, is favorable for collateral growth still
needs to be determined.
Another important class of proteins found associated with MPs
and down-regulated after ECP therapy are complement factors
and immunoglobulins. The involvement of the complement
system in myocardial ischemia and reperfusion injury is well
established [45]. Injury of vessel walls leads to the activation of the
innate immune system. It has recently been shown that in the
autoimmune disease systemic lupus erythematosus, MPs carry
more complement and IgG proteins than controls [46]. Our
findings confirm that these factors do associate with MP and that
the MP load is decreased by ECP therapy. This again implies that
vessel injury could be cured in CAD patients even with low
inflation pressure, also called sham therapy (see above).
In vitro, it has been shown that PMPs promote adhesion and
paracrine activity of angiogenic early outgrowth cells, potentially
leading to improved endothelial restoration after vascular injury
[47]. Most importantly however, an in vivo study demonstrated that
locally injected PMPs are capable of increasing the number of
capillaries after left coronary artery ligation (i.e. coronary
angiogenesis) [16]. Taking these and our own experimental data
and the difference between angiogenesis and arteriogenesis into
account, it may be reasonable to speculate that PMPs might be
involved in shear stress-induced effects of ECP directly at the
endothelium or in regulating arteriogenesis, e.g. via cytokines,
nitric oxide or delivery of activating cellular factors.
The main questions raised by our data are i) why an increase of
PMPs was observed already with low pressure ECP, ii) why there
was no pressure-dependent effect on the increase of PMPs, and iii)
why we observed in patients receiving high pressure ECP therapy
a significant inverse correlation of PMP changes with the
corresponding changes of collateral flow index? First, the diastolic
shear stress during 80 mmHg ECP therapy may be substantial and
strong enough to cause shedding of platelets, and therefore release
of PMPs. This notion is supported by a recently published study
Figure 5. Label-free quantification of individual proteins. Bars
represent mean abundance values (LOG2 values of normalized PMSS) of
individual proteins before (BL) or after (Fup) ECP therapy with
300 mmHg (top) or 80 mmHg inflation pressure (bottom). Whiskers
represent one standard deviation. Proteins displayed are PECA1 (CD31),
ITA2B (CD41), TSP1 (thrombospondin-1), and TGFB1 (transforming
growth factor beta-1).
doi:10.1371/journal.pone.0046822.g005
Figure 6. ECP therapy increases associations of Apo(a) and
APOB to MPs. The sum of Apo(a) and APOB (top panel) was increased
after low and high inflation pressure treatment of CAD patients. Small
molecular weight apolipoproteins (APOA1, APOA2, APOA4, APOC1,
APOC2, APOC3, APOD, APOE, and APOL1) were not changed or slightly
decreased (bottom panel) in case of 80 mmHg inflation pressure
treatment (P= 0.039), respectively.
doi:10.1371/journal.pone.0046822.g006
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demonstrating that a short ex vivo application of low shear stress (10
dyne/cm2 for 3 minutes) already leads to significant formation of
PMPs [48]. In comparison, it was shown during an experimental
setting that high pressure ECP with sufficient diastolic augmen-
tation (i.e. with a peak diastolic to a peak systolic amplitude ratio
.1.2) increases diastolic shear stress to values greater than 50
dyne/cm2 [49]. Second, previous ECP studies with CAD patients
repeatedly reported significant improvement of symptoms even in
the absence of sufficient diastolic augmentation [2], which may not
alone be due to a placebo effect but may also indicate
neurohumoral effects even with sham therapy. Third, the changed
protein composition of PMPs after four weeks of ECP therapy may
point to a chaperon-like function of PMPs in arteriogenesis. The
pressure-dependent diverging correlations between PMP and CFI
changes during the four week therapy period could therefore be
explained by a multi-factorial interrelationship between shear
stress, inflammation, PMP protein cargo related stimulation of
vessel cells, genetic disposition, and duration of treatment.
Therefore, it can be speculated that higher shear stress, e.g.
300 mmHg ECP therapy, increases PMP production faster and
enables activation of arteriogenesis at an earlier point in time
during therapy than lower pressure ECP therapy, e.g. 80 mmHg.
Hence, PMP concentration increases at the on-set of collateral
growth followed by a decrease once collateral growth has reached
a physiologically maximal level, determined by genetic predispo-
sition. The data of patient #14 supports such a hypothesis. Forth,
due to the small sample size, the presence or absence of statistical
significance can be due to chance and needs further validation
with more targeted approaches, e.g. more accurate protein
quantification with LC-MS assays employing selected reaction
monitoring assays on specific target proteins.
In conclusion, our data show that ECP therapy increases PMPs
with a concomitant change of their protein composition in patients
with CAD. PMPs are released even at low shear stress levels.
Although, it is not absolutely clear if these PMPs are a cause or an
effect of the CFI improvement, our data indicate that they might
be players in a multifactorial process where inflammation-like
processes are also involved. Further studies are necessary with
blood sampling at shorter time intervals during therapy and more
participating patients in order to elucidate the exact underlying
cellular mechanisms and to improve the statistical power.
Supporting Information
Figure S1 Correlation of CD31 or CD41 positive MPs
and CFI changes. Correlation of MP changes (Fup minus BL)
positive for CD31 (left side) or CD41 (right side) with
corresponding changes of collateral flow index (CFI) are plotted.
Values are given for ECP therapy at high (300 mmHg) on top or
low inflation pressure (80 mmHg) at bottom, respectively. Filled
triangles represent CFI values from stenosed and open circles from
normal vessels. The values encircled red in the 80 mmHg inflation
pressure group belong to patient #14.
(TIF)
Figure S2 In vitro angiogenesis assay with HUVECs in
Matrigel matrix. HUVECs were seeded in EBM2 medium (left
side) or in EBM2 medium supplemented with growth factors
(EGM2, right side) and incubated for 24 hours. Pictures taken
from the same area after 2, 4, 6, 8, and 12 hours of incubation at
37uC are shown.
(TIF)
Figure S3 Quantitative evaluation of mesh formation by
HUVECs in in vitro angiogenesis assay. Ratios of intact
mesh numbers after 6, 8, and 12 hours against the 4-hour values
were calculated for each well. Crosses represent values with EBM2
(n = 5) and red circles with EGM2 (n = 6) medium. The horizontal
bars represent the means of all measurements at each time point.
(TIF)
Figure S4 Qualitative assessment of MP associated
protein identifications with Venn diagrams. Our own
core and complete protein sets were compared with the
Uniprot_SwissProt protein identifications of several MP proteome
studies published. Østergaard and Little analyzed MPs isolated
from human plasma. The complete SwissProt protein sets from
endothelial derived MPs (EMP) and activated platelet derived MPs
(PMP) from Peterson and Garcia, respectively, were also included
in this comparison. Results demonstrate clearly that our MP
associated proteins corresponded well with the ones described
from other MP and PMP studies, but were less congruent with
endothelial cell derived MPs.
(TIF)
Figure S5 Label-free quantification of protein classes.
Boxplot representations of normalized protein abundance values
(LOG2 values) of structural cell proteins (top panels) and cell
surface proteins (bottom panels). The group of myosin proteins
encompasses MYL6, MYH9, MYH10, MYH13, MYH14, MYL9,
and ML12A that were identified in 12, 12, 6, 7, 10, 9, and 12 out
of the 12 analyzed MP samples, respectively. Tubulins were
TBA1A, TBA1B, TBA4A, TBA4B, TBB1, TBB4A, TBB4B,
TBB5, TBB6, and TBB8, identified in at least eight MP samples.
Platelet markers CD36, CXCL7, ITA2B, PECA1, PLF4 were
identified in at least 12 MP samples, except LYAM3 with only
seven. Integrins were ITA2, ITA2B, ITA6, ITB1, ITB3, and
identified in at least 8 MP samples. When one of the proteins was
not identified, its value was set at zero for statistical analysis of P
values. P values are given above each box if the likelihood for a
statistical difference between BL and Fup was close or better to
95%.
(TIF)
Table S1 List of all identified proteins.
(PDF)
Table S2 Cellular component gene ontology enrichment
analysis result with BINGO for identified core proteins.
(TXT)
Table S3 Molecular function gene ontology enrichment
analysis result with BINGO for identified core proteins.
(TXT)
Table S4 Biological process gene ontology enrichment
analysis result with BINGO for identified core proteins.
(TXT)
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